While the clinical spectrum of CSHS varies greatly from individual to individual in terms of the extent and location of bone and skin lesions and the degree of FGF23-mediated hypophosphatemia, in the majority of patients, the most debilitating manifestation is hypophosphatemia (2). This evidence concerns the gene FGF23 and hypophosphatemia.